Two Ukrainian veterans with amputations climbed the Himalayas
Two veterans of Defence Intelligence of Ukraine, both amputees, have conquered the Himalayas. The expedition included veterans Ivan Tarn from the Artan special operations forces unit and Oleksandr Dashko from the Kraken special operations forces unit.
Source: Defence Intelligence of Ukraine
Details: The soldiers were accompanied by professional climbers Tetiana Yalovchak and Taras Pozdnii. Together, they climbed to Everest Base Camp, located at an altitude of 5,280 metres.
"You see all this in front of you, but it's hard to believe your eyes. It's like looking at a very, very real photo wallpaper. Incredible beauty," Ivan Tarn shared his impressions.
Participation in the project was a serious challenge for the veterans.
"Many people didn't believe in this project or in me because I have a very extensive amputation. No matter who I told about this adventure, they said: 'People with two legs can't even climb up there, and you don't have a leg; you'll ruin your health even more – don't go.
It was challenging for me, but other guys with amputations need to see this climb. They need to see that there is life after amputation," emphasised Oleksandr Dashko.
Oleksandr Dashko.
Photo: Defence Intelligence of Ukraine on Facebook
The expedition took place as part of the Limitless project, which aims to draw attention to the problems faced by amputees and raise 3 million UAH (about US$72,000) to combat phantom pain.
"Until now, Ukrainians with amputations had never climbed this peak. This is more than just a track. It is proof that there are no limits for those who have a goal and the strength to keep going. Proof that life after amputation is possible.
This climb is for everyone who is currently fighting, recovering and trying to live a full life despite everything," the project page says.
Background: Earlier, there was the story of Ukrainian defender Roman "Dobriak" Kolesnyk, who lost his leg on the front line and went on a hike in the Carpathians on a prosthesis to raise funds for the military.
Support Ukrainska Pravda on Patreon!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
MRO acquires clinical data management platform Q-Centrix from TPG Growth
US-based clinical data exchange company MRO has acquired Q-Centrix, an enterprise clinical data management platform previously owned by TPG Growth. Q-Centrix is a comprehensive data management platform designed to reduce complexity, expedite decisions and advance clinical outcomes. MRO said the acquisition would enable hospitals and health systems to convert fragmented clinical data into actionable insights, expediting the exchange of clinical data across the sector. The deal is expected to create scalable value for healthcare providers, payers and life sciences, supporting more precise decision-making and broader clinical applications. MRO CEO Jason Brown said: 'At MRO, we believe there is tremendous untapped value in unlocking and leveraging clinical data that resides in fragmented, siloed systems today. 'Combining MRO's leading clinical data exchange solutions and Q-Centrix's clinical data management capabilities creates a category-defining, fit-for-purpose platform, enabling high fidelity, low latency acquisition, abstraction, curation and exchange of clinical data to power better patient care and reduce costs across the healthcare ecosystem.' The combined entity will provide services to more than 2,000 health systems and hospitals, as well as over 7,000 clinics and almost 250 payers. By enriching and curating clinical data, MRO and Q-Centrix aim to deliver scalable value, facilitating precise decision-making and wider clinical applications. Q-Centrix CEO Milton Silva-Craig said: 'MRO and Q-Centrix share a commitment to advancing the industry in service of our customers. 'That focus is fuelling the creation of a first-of-its-kind platform—seamlessly integrating systems and delivering structured, highly valuable data sets to support clinical care, operational performance, breakthrough research, and regulatory compliance. 'Purpose-built around our customers' most pressing needs, this is innovation where it matters most.' The acquisition is supported by healthcare technology investors such as private equity company Parthenon Capital, which has reaffirmed its support for MRO with a new investment. The parties have not disclosed the value of the deal. "MRO acquires clinical data management platform Q-Centrix from TPG Growth" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Climate change leads to spread of infection-causing fungi, scientists say
Climate change may be putting millions more people at risk from an infection-causing fungi, which is likely spreading due to warming global temperatures, scientists say. There will likely be an increased risk of infection due to harmful fungi in the coming years due to climate change, according to researchers from the University of Manchester. MORE: What to know about Fusarium graminearum, the biological pathogen allegedly smuggled into the US The scientists mapped the effects of rising temperatures on global distribution of three infection-causing fungi under different climate scenarios through 2100: Aspergillus flavus, Aspergillus fumigatus and Aspergillus niger, according to the paper, which has been published on preprint platform Research Square and not yet been peer-reviewed. Aspergillus, a fungal mold that thrives in warm, damp climates, is already found worldwide -- including in the U.S. -- and can impact humans, animals, livestock and plants. But current emissions projections indicate that within 15 years a "significant spread" of certain fungal pathogens could occur in Europe and beyond, the researchers said. Under this scenario, the spread of A. flavus could increase by 16%, putting 1 million more people in Europe at risk of infection, according to the paper. MORE: USDA orders removal of climate change mentions from public websites Another fungus, A. fumigatus, could increase by 77.5% and potentially expose 9 million people in Europe, the researchers said. A. fumigatus affects the lungs and is one of the most common pathogens responsible for life-threatening infections in humans, according to the paper. Fungal spores transported through the air can cause infections in humans when inhaled -- especially for vulnerable populations and people with weakened immune systems and lung disease, according to the Centers for Disease Control and Prevention. Fungi are "incredibly adaptable organisms" that allow them to colonize new geographies and survive environment changes, the researchers said. The emergence and spread of the fungus Candida auris has also occurred as a result of warming temperatures, Van Rhijn said. "Changes in environmental factors, such as humidity and extreme weather events, will change habitats and drive fungal adaptation and spread," Norman van Rhijn, professor at the University of Manchester's School of Biological Sciences and lead author of the paper, said in a statement. MORE: Climate change could aggravate over half of known human pathogens, scientists say The trend is especially concerning due to a rise in antifungal resistance -- driven by the use of fungicides in agriculture to protect crops -- as well as a "severe lack" of treatment options for fungal infections, the researchers said. But fungi are relatively under researched compared to viruses and parasites, Van Rhijn said. Less than 10% of up to 3.8 million species have been described, the researchers said. "Raising awareness and developing effective interventions for fungal pathogens will be essential to mitigate the consequences of this," he said. Climate change leads to spread of infection-causing fungi, scientists say originally appeared on
Yahoo
2 days ago
- Yahoo
Diagnostic Electrocardiograph/ECG Market worth US$15.18 billion by 2032 with 7.4% CAGR
DELRAY BEACH, Fla., June 13, 2025 /PRNewswire/ -- The global Diagnostic Electrocardiograph/ECG Market, valued at US$8.59 billion in 2024 stood at US$9.19 billion in 2025 and is projected to advance at a resilient CAGR of 7.4% from 2025 to 2032, culminating in a forecasted valuation of US$15.18 billion by the end of the period. The growth in the ECG diagnostic market can be attributed to several critical factors. The rising prevalence of chronic conditions, particularly CVDs, is a significant driver. Additionally, there is a marked shift towards home healthcare solutions, propelled by advancements in wearable technology and the broader digital transformation within the healthcare sector. The burgeoning geriatric demographic, which is increasingly susceptible to cardiac disorders, further amplifies the demand for ECG diagnostics across various healthcare environments. Technological innovations, specifically the advent of portable ECG devices and AI-enhanced ECG interpretation, are enhancing diagnostic precision and improving patient accessibility. Moreover, government initiatives aimed at promoting cardiac health, coupled with a growing acceptance of point-of-care diagnostic methodologies, are anticipated to bolster market growth moving forward. Download PDF Brochure: Browse in-depth TOC on "Diagnostic Electrocardiograph/ECG Market" 150 - Tables60 - Figures250 - Pages By Product, the diagnostic ECG market is categorized into diagnostic ECG devices and diagnostic ECG software & services, with the diagnostic ECG devices segment commanding the largest market share. This predominance is attributable to the critical role these devices play in routine cardiac diagnostics, the swift identification of arrhythmias, and long-term cardiac monitoring. Standard resting ECGs serve as fundamental assessments in both primary care and specialized medical environments, while Holter monitors facilitate extensive and continuous cardiac surveillance over extended periods. The demand for these diagnostic tools is significantly influenced by the rising geriatric population, which correlates with an increase in CVD prevalence within this demographic. According to WHO, over 80% of CVD-related fatalities result from heart attacks and strokes, with one-third of these deaths occurring prematurely in individuals under 70 years of age; this statistic underscores the urgent need for effective cardiac monitoring solutions in the face of growing cardiovascular health challenges. By lead type, the diagnostic ECG market is categorized based on lead types into 12-lead, 5-lead, 3-lead, 6-lead, and single-lead ECG devices. Notably, 12-lead ECG systems dominate the market due to their superior diagnostic capabilities, allowing for precise measurement of cardiac electrical activity. Regarded as the gold standard for the advanced diagnosis of cardiac pathologies, including myocardial infarctions and arrhythmias, these systems are widely endorsed by clinical guidelines for use in hospitals and cardiology clinics. Their approval for emergency and critical care applications further cements their market leadership. Key manufacturers of 12-lead diagnostic ECG devices include Koninklijke Philips N.V. (Netherlands), ACS Diagnostics (US), OSI Systems, Inc. (US), and GE Healthcare (US). By type, the diagnostic ECG market is further segmented into portable, wearable, and implantable ECG devices. In 2024, the portable ECG devices segment accounted for the largest market share, driven by their convenience, mobility, and diverse applications in both clinical settings and home care. Unlike traditional ECG machines, which are typically bulkier and stationary, portable devices enable on-demand or continuous cardiac monitoring from virtually any location. A significant advantage of these devices is their ability to wirelessly record and transmit ECG data to healthcare providers, facilitating remote patient monitoring. This capability not only allows for timely interventions but also minimizes the need for frequent hospital visits, which is particularly beneficial for patients with chronic heart conditions. As a result, the emphasis on remote patient care and the demand for personalized healthcare solutions are the primary factors propelling the growth of portable ECG devices, solidifying their dominant position within the diagnostic ECG market. By end user, the diagnostic ECG market is segmented into hospitals, primary care centers, cardiac centers, ambulatory surgery centers, urgent care settings, and home care settings. The hospitals segment held the largest market share primarily due to the high volume of cardiovascular patient admissions and the presence of state-of-the-art diagnostic infrastructure. The integration of ECG systems with other cardiac diagnostic modalities enhances their utility in both inpatient and outpatient settings, especially within emergency and ICUs. The increasing rates of hospital admissions for cardiac conditions, combined with the emphasis on early detection and timely intervention, position hospitals as the predominant end users of ECG technologies; this trend is a key driver of overall market expansion in the diagnostic ECG market. By geography, the diagnostic ECG market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The North American market has successfully secured a substantial share, driven by several key factors. One major contributor is the growth in the geriatric population, which is leading to an increased demand for healthcare services and diagnostic tools. Alongside this demographic shift, there has been a notable rise in the prevalence of chronic diseases, such as CVDs and diabetes, that require regular monitoring and management through advanced diagnostic ECG solutions. Additionally, the enhancement of healthcare infrastructure in the region plays a crucial role in facilitating better access to these diagnostic services. Hospitals & clinics are increasingly equipped with state-of-the-art technology and resources, enabling healthcare providers to offer timely and effective care. Furthermore, supportive government initiatives aimed at improving healthcare accessibility also have a positive impact on the market. Policies designed to reduce barriers to healthcare services and promote innovative diagnostic technologies are helping to ensure that patients can receive necessary care without significant obstacles. The strategic expansion of key players in the North American market, which includes both established companies and emerging startups, is anticipated to further bolster market growth. The active presence of these industry leaders not only enhances competition but also drives innovation in product development, ultimately benefiting patients and healthcare providers alike. Overall, these factors collectively signify a robust growth trajectory for the ECG diagnostic solutions market in North America. Request Sample Pages : As of 2024, diagnostic ECG market was dominated by GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Baxter (US), FUKUDA DENSHI (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), NIHON KOHDEN CORPORATION (Japan), OSI Systems, Inc. (US), Bittium (Finland), iRhythm Technologies, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Midmark Corporation (US), BPL Medical Technologies (India), SCHILLER (Switzerland), ACS Diagnostics (US), Allengers (India), and Bionet Co., Ltd. (South Korea), among others. GE Healthcare (US): GE Healthcare is a well-established entity in the diagnostic ECG sector, boasting over 125 years of industry experience and a formidable reputation within the global healthcare landscape. The company effectively utilizes its extensive global footprint in medical technology, diagnostics, and digital solutions, catering to a diverse clientele across 160 countries while adhering to sustainable operational practices. Central to GE Healthcare's strategy is a robust emphasis on R&D to optimize existing offerings and innovate new products and services. This commitment allows the company to stay responsive to evolving customer demands and to capitalize on emerging market opportunities. In a notable move for 2024, GE Healthcare invested approximately USD 969 million to enhance manufacturing capabilities and local R&D initiatives in India over the next five years. The company's growth strategy encompasses a range of collaborations, agreements, expansions, and acquisitions to strengthen its operational reach and market presence. These strategic endeavors not only expand the product portfolio but also fortify the company's competitive standing in the market. In a recent development, GE Healthcare partnered with the Mayo Clinic in September 2023 to leverage advanced technologies and improve the precision of diagnostics and treatment processes for healthcare providers. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. (Royal Philips) serves as the parent organization of the Philips Group, strategically operating across four core domains: Personal Health, Diagnosis & Treatment, Connected Care, and Others. Within the Connected Care segment, Philips provides advanced diagnostic solutions, including cardiographs, Holter monitoring systems, and stress-testing ECGs. The company's growth strategy is heavily centered on forming strategic partnerships in high-potential markets and fostering collaborative efforts to drive innovation. A notable example of this approach is the 2023 partnership with NYU Langone Health to leverage innovative technologies and enhance patient care over an eight-year span. Additionally, in January 2025, Philips is set to present its latest innovations at Arab Health 2025. These advancements emphasize the integration of smart systems, automation, and cloud-based informatics into healthcare delivery, targeting reductions in clinician workload and improvements in operational workflows, ultimately leading to enhanced patient outcomes. Key subsidiaries within the Philips ecosystem include Philips Oral Healthcare, LLC (US), Philips GmbH (Germany), Philips Ultrasound, Inc. (US), and Philips Consumer Lifestyle B.V. (Netherlands). The company maintains a comprehensive operational footprint across North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Shenzhen Mindray Bio-Medical Electronics Co. (China) Shenzhen Mindray Bio-Medical Electronics is a prominent entity in the diagnostic ECG segment, distinguished by its diverse operational structure across three primary business verticals: Patient Monitoring and Life Support, In-vitro Diagnostics, and Medical Imaging Systems. Within the Patient Monitoring & Life Support sector, the company delineates its offerings into Patient Monitoring Systems, ECG devices, and ancillary products. Mindray dedicates more than 10% of its revenue to R&D, which underpins its commitment to innovation and sustains a formidable portfolio of over 3,000 patents. This investment not only fuels technological advancement but also strengthens its competitive edge. The company has also established strategic partnerships to enhance its market penetration and product offerings. Notably, its collaboration with Amazon Business facilitates improved access to medical equipment for healthcare systems, hospitals, and practitioners, streamlining procurement and distribution channels in a rapidly evolving healthcare landscape. For more information, Inquire Now! Related Reports: Cardiac Monitoring & Cardiac Rhythm Management Devices Market Patient Monitoring Devices Market Brain Monitoring Market Patient Temperature Monitoring Market MRI Systems Market Get access to the latest updates on Diagnostic Electrocardiograph/ECG Companies and Diagnostic Electrocardiograph/ECG Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content to download multimedia: SOURCE MarketsandMarkets
